Guru Ownership Trend
Guru Analysis for BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q2 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $1.51 M.
Top institutional holders include Chuck Royce and Louis Moore Bacon.
Institutional sentiment is currently Slightly Bearish. This is evidenced by a $2.25 M net outflow during the quarter.
On the selling side, Renaissance Technologies (RenTech) reduced exposure by 42.5%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q2 2026)
Guru Consensus (Q2 2026)
FAQs for BridgeBio Oncology Therapeutics, Inc. (BBOT)
Major holders include Chuck Royce ($2.93 M), Louis Moore Bacon ($762,000), Renaissance Technologies (RenTech) ($446,532). According to the latest reported data, 3 tracked investment managers collectively hold approximately 543,541 shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $2.25 M, with 0 managers increasing positions and 2 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 0 fully exited BBOT. The total reported sell value was $2.25 M.
No tracked managers opened new positions or increased their holdings in BBOT during the most recent reporting period.